𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Efficacy and Safety of Edifoligide, an E2F Transcription Factor Decoy, For Prevention of Vein Graft Failure Following Coronary Artery Bypass Graft Surgery, Prevent IV: A Randomized Control Trial

✍ Scribed by Klein-Soyer, C

Book ID
122286138
Publisher
Elsevier Science
Year
2006
Tongue
English
Weight
34 KB
Volume
43
Category
Article
ISSN
1097-6809

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A multicentre, randomized, double-blind
A multicentre, randomized, double-blind placebo-controlled trial evaluating rosiglitazone for the prevention of atherosclerosis progression after coronary artery bypass graft surgery in patients with type 2 diabetes. Design and rationale of the VeIn-Coronary aTherOsclerosis and Rosiglitazone after bypass surgerY (VICTORY) trial
✍ Olivier F. Bertrand; Paul Poirier; Josep Rodés-Cabau; Stéphane Rinfret; Lawrence 📂 Article 📅 2009 🏛 Pulsus Group Inc 🌐 English ⚖ 803 KB